Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
Previous Symbol
CUSIPN/A
Phone510-450-3500
Debt
Debt-to-Equity Ratio1.01
Current Ratio8.95
Quick Ratio8.74
Price-To-Earnings
Trailing P/E Ratio-2.47
Forward P/E Ratio-1.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$570,000.00
Price / Sales470.54
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.90 per share
Price / Book3.38
Profitability
EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net Margins-617.27%
Return on Equity-106.74%
Return on Assets-51.66%
Miscellaneous
Employees147
Outstanding Shares27,340,000
Market Cap$272.81 million
OptionableOptionable
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, beating the Zacks' consensus estimate of ($1.34) by $0.12. The specialty pharmaceutical company earned $10.61 million during the quarter, compared to analysts' expectations of $10.10 million. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 106.74%. View Adamas Pharmaceuticals' Earnings History.
When is Adamas Pharmaceuticals' next earnings date?
What price target have analysts set for ADMS?
9 brokers have issued twelve-month target prices for Adamas Pharmaceuticals' shares. Their predictions range from $18.00 to $49.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $31.7143 in the next year. This suggests a possible upside of 223.3% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.
What is the consensus analysts' recommendation for Adamas Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamas Pharmaceuticals.
What are Wall Street analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (11/6/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation ascribes a $1.15B valuation to GOCOVRI in PD $400M value for ADS-5102 based on a risk-adjusted net present value (rNPV) that employs a 15% discount rate, 30% effective tax rate and 30% cost of sales and marketing. We utilize a 60% probability of success for ADS-5102." (11/5/2018)
- 3. Mizuho analysts commented, "We hosted an investor lunch with a practicing neurologist who discussed his experience with Gocovri. Specifically, he reported hallucinations in approximately 50% of his patients, vs. the 21% reported in the product label. This doctor attributed the side effect to rapid titration to the 274 mg daily dose, and has started to experiment with starting patients on the lowest 68.5 mg dose of the product (but was concerned that efficacy was modest at this level). This physician treated ~20 patients so far, but only 5-7 of these currently remain on the drug. We learned that for his patients 65 years had to be stepped down in dose or stop taking the product." (8/17/2018)
Has Adamas Pharmaceuticals been receiving favorable news coverage?
Media stories about ADMS stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a news sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the near future.
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Deciphera Pharmaceuticals (DCPH), Amphastar Pharmaceuticals (AMPH), Apellis Pharmaceuticals (APLS), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX) and Dicerna Pharmaceuticals (DRNA).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 54)
- Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
- Dr. Rajiv Patni, Chief Medical Officer (Age 49)
- Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
- Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 43)
Who are Adamas Pharmaceuticals' major shareholders?
Adamas Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (8.94%), BlackRock Inc. (6.91%), Macquarie Group Ltd. (6.53%), Vanguard Group Inc. (3.69%), Janus Henderson Group PLC (3.32%) and Alliancebernstein L.P. (3.10%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni, Richard King and William J Dawson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
Which major investors are selling Adamas Pharmaceuticals stock?
ADMS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, JPMorgan Chase & Co., Bamco Inc. NY, Fisher Asset Management LLC, Credit Suisse AG, Oak Ridge Investments LLC and Dupont Capital Management Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Insider Buying and Selling for Adamas Pharmaceuticals.
Which major investors are buying Adamas Pharmaceuticals stock?
ADMS stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Marshall Wace LLP, Point72 Asset Management L.P., Alliancebernstein L.P., Dimensional Fund Advisors LP, First Trust Advisors LP, SCP Investment LP and Emerald Mutual Fund Advisers Trust. View Insider Buying and Selling for Adamas Pharmaceuticals.
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $9.81.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $272.81 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.
What is Adamas Pharmaceuticals' official website?
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
